Pityriasis rosea after mRNA COVID‐19 vaccination
Lina Abdullah, Divina Justina Hasbani, Mazen Kurban, Ossama Abbas
Abstract
Pityriasis rosea after mRNA COVID-19 vaccinationDear Editor, With the ominous socioeconomic and medical consequences associated with the current COVID-19 pandemic and in an effort to alleviate its associated morbidity and mortality, several vaccines have been developed and used over the past few months.Among these, the mRNA vaccines, given in twodose series, have been reported to provide 95% protection from COVID-19. 1 Commonly described vaccine-related adverse effects include pain, swelling, and/or redness at injection site,
Topics & Concepts
MedicineFamily medicineDermatologyCenter (category theory)CrystallographyChemistryDermatological and COVID-19 studiesBartonella species infections researchInflammatory Myopathies and Dermatomyositis